CN107056959A - Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation - Google Patents
Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation Download PDFInfo
- Publication number
- CN107056959A CN107056959A CN201710080999.9A CN201710080999A CN107056959A CN 107056959 A CN107056959 A CN 107056959A CN 201710080999 A CN201710080999 A CN 201710080999A CN 107056959 A CN107056959 A CN 107056959A
- Authority
- CN
- China
- Prior art keywords
- jerusalem artichoke
- active ingredient
- rsv
- virus
- antiviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Sustainable Development (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to active ingredient of Chinese herbs production extraction process and active ingredient identification field, it is related to the new technology and the new application in pharmaceutical field of identification and the extracts active ingredients separation of the viral active ingredient of the type virus of jerusalem artichoke anti-herpes simplex I, Respiratory Syncytial Virus(RSV), enteron aisle EV 71, and in particular to extracted using the mode of antiviral tracking and prepare the type virus of jerusalem artichoke anti-herpes simplex I, Respiratory Syncytial Virus(RSV), the active ingredient of the viruses of enteron aisle EV 71.Specific steps include water refluxing extraction jerusalem artichoke, alcohol precipitation, it is antiviral, dissolving precipitation, soda acid removal of impurities, petroleum ether are except oil-soluble impurities, Sevag methods de- albumen, activated carbon decolorizing, white solid is finally freeze-dried to obtain, molisch reactions and antiviral study in vitro is carried out, it is jerusalem artichoke polysaccharide to determine active ingredient.The viral active ingredient of jerusalem artichoke moderate resistance herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), enteron aisle EV 71, the features such as it has safe as natural extract are found that present invention employs the method for antiviral tracking.
Description
Technical field
The present invention relates to active ingredient of Chinese herbs production extraction process and active ingredient identification field, it is related to jerusalem artichoke antiviral
New approaches new method and the new application in pharmaceutical field that active component is extracted, and in particular to utilize the mode of antiviral tracking
The type virus of extraction separation and purification jerusalem artichoke anti-herpes simplex I, Respiratory Syncytial Virus(RSV), the active ingredient of enteron aisle EV-71 viruses.
Background technology
All receive various viral invasions all over the world since the last few years, such as SARS virus, H1N1 etc., often
Secondary viral outburst can all cause the panic and death of the mankind.So it is extremely urgent to find suitable antiviral drugs.
Herpes simplex virus can cause a variety of diseases of the mankind, such as gingivostomatitis, keratoconjunctivitis, encephalitis and system genitale togetherness
Dye and neonatal infection.After infection host, latent infection is often set up in nerve cell, is occurred again after activation asymptomatic
Toxin expelling, propagation chain is maintained in crowd, the circulation gone round and begun again.
Respiratory Syncytial Virus(RSV) is to cause one of most important pathogen of infant's acute lower respiratory infection, can there is height
Heat, rhinitis, pharyngitis and laryngitis, show as capillary bronchitis and pneumonia later.A small number of sick children can concurrently tympanitis, pleurisy and the heart
Myositis etc..After adult and older children infect, the infection of the upper respiratory tract is mainly shown as, can also cause interstitial pneumonia and capillary branch
Tracheitis etc. can also cause the elderly and immune deficiency patient to be in hospital and pneumonia death simultaneously.
The enterovirus group that enterovirus belongs in virology in Parvoviridae, EV-71 be in current enterovirus group most
The virus that evening finds, its infectious pole and it is strong and pathogenicity rate is higher, the complication especially in terms of nervous system.EV-71
Virus is to cause one of main pathogens of Children, can also cause aseptic meningitis, BBE and spinal cord
A variety of the nervous system diseases such as the paralysis of poliomyelitis sample.
Jerusalem artichoke is commonly called as Jerusalem artichoke, Jerusalem artichoke, belongs to composite family Compositac, is that a kind of Helianthus perennial root draft is planted
Thing, jerusalem artichoke typically yields positive results in the fall, and this flower-shape is like chrysanthemum, and edible part is generally the stem tuber grown in stem tuber, soil and is rich in
The Multiple components such as many sugar and starches, jerusalem artichoke has anti-oxidant, anticancer, antibacterium and antimycotic isoreactivity, can be used as antipyretic, town
Bitterly, anti-inflammatory and antitetanic drug therapy fracture, swelling, skin trauma and pain etc..
Jerusalem artichoke has certain therapeutic action to herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), enteron aisle EV-71 viruses,
Experiment shows that the active ingredient that jerusalem artichoke is extracted has very to herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), enteron aisle EV-71 viruses
Good therapeutic action.
The content of the invention
The technical problems to be solved by the invention be specify that the type virus of jerusalem artichoke anti-herpes simplex I, Respiratory Syncytial Virus(RSV),
The active ingredient of enteron aisle EV-71 viruses, and provide a kind of side using antiviral tracking for the separation and Extraction of the active ingredient
Formula prepares the new method of the antiviral active ingredient of jerusalem artichoke.The active ingredient extracts isolated from feverfew plant jerusalem artichoke
It can be used for herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), the treatment of enteron aisle EV-71 virus infection.This method can be more
Easy carries out separation and Extraction to above active ingredient.
It is an advantage of the invention that the present invention has been isolated in jerusalem artichoke first there is the type of anti-herpes simplex I virus, respiratory tract to close
A kind of active ingredient of cellular virus, enteron aisle EV-71 viruses, and invented a kind of method of antiviral tracking the active ingredient is entered
Preparation is gone, this separation method purpose is strong, simply saves substantial amounts of manpower and materials, has been separated better than traditional system.Prepare
Obtained active ingredient there is preferably treatment to make herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), enteron aisle EV-71 viruses
With.
The type virus of jerusalem artichoke anti-herpes simplex I of the present invention, Respiratory Syncytial Virus(RSV), the active ingredient of enteron aisle EV-71 viruses are
Jerusalem artichoke polysaccharide, the preparation method of the active ingredient, comprises the following steps：
（1）Take a certain amount of jerusalem artichoke medicinal material 10 times of water heating and refluxing extraction 2 times, 2 hours for the first time, second 1.5 hours；
（2）The extract solution merged twice is concentrated under reduced pressure, and is concentrated into the medicinal material that every milliliter of decoction contains 1 gram, then adds ethanol regulation
The concentration of ethanol is, 80%, stand 48 hours.It is filtrated to get precipitation and supernatant；
（3）Supernatant is reclaimed into ethanol, precipitation water is dissolved, Antiviral breeding is carried out respectively.It is disease-resistant that experiment display is precipitated
Toxic effect fruit is preferable；
（4）Under agitation, milk of lime is slowly instilled into precipitation lysate, regulation pH value to 11.0 stands in a moment, is put into 80
1 h is incubated in DEG C water-bath, suction filtration removes insoluble matter, collects filtrate；Phosphoric acid is slowly dropped into filtrate, and is stirred continuously, is adjusted
PH value is saved to 8.0, is separated with centrifuge (4000 r/min, 15 min), collects centrifugate；
（5）The petroleum ether of 10 times of amounts is added into centrifugate, is extracted with separatory funnel, stratification, upper strata is petroleum ether layer, under
Layer is water layer, collects lower floor, is repeated 3 times, and removes oil-soluble impurities；
（6）Protein in extract solution, extract solution are removed using Sevag methods：Sevag reagent=5:1（v/v）, Sevag reagents are
Chloroform：N-butanol=5:1（v/v）.Chloroform and n-butanol are well mixed, are poured slowly into the case where being stirred continuously equipped with extract solution
In beaker, preservative film sealing, with the min of magnetic stirrer 40, is poured into separatory funnel, static layering.3 layers of liquid point, on
Layer is extraction liquid layer, and intermediate layer is denatured protein layer, and lower floor is Sevag reagent layers, collects upper solution, and centrifuge out
A small amount of denatured protein, is repeated 5 times by above-mentioned steps, makes the removal of protein in extract solution complete；
（7）Weigh activated carbon（Consumption is 5 g/L）Pour into extract solution, after stirring, be put in 80 DEG C of thermostat water baths and protect
30 min of temperature, suction filtration, room temperature is cooled to by filtrate while hot；
（8）Extract solution is poured into refrigerator tray, and is put in refrigerator and freezes 24 h, freeze it is solid after be put in freeze drier and do
It is dry, it is dried after powder is fitted into labelled standby in ep pipes；
（9）Will（8）Obtained powder carries out molisch reactions, is as a result positive, and it is jerusalem artichoke polysaccharide to determine the composition；
（10）Will（8）Obtained powder dissolving carries out antiviral study in vitro, and it is anti-well that experimental result shows that jerusalem artichoke polysaccharide has
Virus effectiveness.
Embodiment
Example 1（1）Weigh a certain amount of jerusalem artichoke plus 10 times of amount heating and refluxing extractions twice, 2 hours for the first time, second
1.5 hours, merge extract solution twice, be concentrated under reduced pressure into the medicinal material that every milliliter of decoction contains 1 gram, plus ethanol adjusts solution ethanol
Concentration is 80%, stands 48 hours.
（2）Will（1）Obtained precipitation solution decompression suction filtration, is precipitated, by precipitation distilled water ultrasonic dissolution.
（3）Will（2）Obtained solution carries out soda acid removal of impurities, petroleum ether except oil-soluble impurities, Sevag methods take off albumen, activity
Carbon decoloring, is finally freeze-dried to obtain white solid.
（4）Will（3）In obtained white powder carry out molisch reactions and antiviral study in vitro, experimental result is shown
Its type virus of anti-herpes simplex I, Respiratory Syncytial Virus(RSV), enteron aisle EV-71 virus effectiveness are preferable.
Claims (10)
1. there is the type virus of anti-herpes simplex I, Respiratory Syncytial Virus(RSV), the active ingredient of enteron aisle EV-71 viruses in a kind of jerusalem artichoke
With a kind of process of the mode extraction separation and purification active ingredient using antiviral tracking, it is characterised in that this effectively into
It is divided into jerusalem artichoke polysaccharide.
2. first with water extract-alcohol precipitation, soda acid removal of impurities, petroleum ether are then carried out except oil-soluble impurities, Sevag methods take off albumen, activity
Carbon decoloring, is finally freeze-dried to obtain white solid, and jerusalem artichoke polysaccharide is accredited as through molisch reactions.
3. active ingredient according to claim 1 is characterized in that the active ingredient is jerusalem artichoke polysaccharide.
4. extraction separation method according to claim 1, it is characterised in that the solid-liquid ratio of jerusalem artichoke water refluxing extraction is 1：10, carry
Take number of times twice, extraction time is 2 hours for the first time, second 1.5 hours.
5. extraction separation method according to claim 1, it is characterised in that the concentrate concentration of Aqueous extracts is that 1ml decoctions contain
1g medicinal material, alcohol precipitation concentration is 80%, and the alcohol precipitation time is 48 hours.
6. extraction separation method according to claim 1, it is characterised in that decompression suction filtration is carried out after alcohol precipitation, obtain precipitation and
Supernatant, then carries out Antiviral breeding and obtains being precipitated as antivirus effective position.
7. extraction separation method according to claim 1, it is characterised in that carry out soda acid removal of impurities with sodium hydroxide and phosphoric acid, so
Remove oil-soluble impurities with petroleum ether again afterwards.
8. extraction separation method according to claim 1, it is characterised in that take off albumen with Sevag methods and use activated carbon decolorizing,
Finally it is freeze-dried to obtain white solid.
9. extraction separation method according to claim 1, it is characterised in that molisch reactions are the positive, identify this effectively into
It is divided into and is divided into jerusalem artichoke polysaccharide.
10. extraction separation method according to claim 1, it is characterised in that jerusalem artichoke polysaccharide is subjected to Antiviral breeding, obtained
Jerusalem artichoke polysaccharide is the type virus of anti-herpes simplex I, Respiratory Syncytial Virus(RSV), the active ingredient of enteron aisle EV-71 viruses.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710080999.9A CN107056959A (en) | 2017-02-15 | 2017-02-15 | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710080999.9A CN107056959A (en) | 2017-02-15 | 2017-02-15 | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107056959A true CN107056959A (en) | 2017-08-18 |
Family
ID=59598603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710080999.9A Pending CN107056959A (en) | 2017-02-15 | 2017-02-15 | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107056959A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111346086A (en) * | 2020-04-30 | 2020-06-30 | 鲁东大学 | Application of compound in preparation of antiviral drug |
| CN112841229A (en) * | 2021-01-27 | 2021-05-28 | 烟台恩倍得化工科技有限公司 | Composition containing jerusalem artichoke leaf extracting solution and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101731509A (en) * | 2008-11-20 | 2010-06-16 | 郝琳琳 | Method for extracting inulin from Canada potato |
| CN103141383A (en) * | 2013-02-28 | 2013-06-12 | 王茜 | Method for producing jerusalem artichoke by tissue culture technology |
| CN104366195A (en) * | 2014-11-27 | 2015-02-25 | 高铭鸿 | Intestinal probiotics and Jerusalem artichokes polysaccharide tablets |
| CN105287722A (en) * | 2015-08-27 | 2016-02-03 | 李宏 | Danshen root-Jerusalem artichoke polysaccharide tablet |
-
2017
- 2017-02-15 CN CN201710080999.9A patent/CN107056959A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101731509A (en) * | 2008-11-20 | 2010-06-16 | 郝琳琳 | Method for extracting inulin from Canada potato |
| CN103141383A (en) * | 2013-02-28 | 2013-06-12 | 王茜 | Method for producing jerusalem artichoke by tissue culture technology |
| CN104366195A (en) * | 2014-11-27 | 2015-02-25 | 高铭鸿 | Intestinal probiotics and Jerusalem artichokes polysaccharide tablets |
| CN105287722A (en) * | 2015-08-27 | 2016-02-03 | 李宏 | Danshen root-Jerusalem artichoke polysaccharide tablet |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111346086A (en) * | 2020-04-30 | 2020-06-30 | 鲁东大学 | Application of compound in preparation of antiviral drug |
| CN111346086B (en) * | 2020-04-30 | 2022-10-21 | 鲁东大学 | Application of compound in preparation of antiviral drug |
| CN112841229A (en) * | 2021-01-27 | 2021-05-28 | 烟台恩倍得化工科技有限公司 | Composition containing jerusalem artichoke leaf extracting solution and preparation method and application thereof |
| CN112841229B (en) * | 2021-01-27 | 2021-12-28 | 烟台恩倍得化工科技有限公司 | Composition containing jerusalem artichoke leaf extracting solution and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102114044B (en) | Artificially processed bear bile powder and preparation method thereof | |
| CN106668657A (en) | Beverage capable of lowering uric acid and lipid and preparation method of beverage | |
| CN106420876A (en) | Drinking liquid with uric acid decreasing and lipid lowering effects and preparation method of drinking liquid | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| CN104367987B (en) | Formulation of astragalus root for animals and preparation method thereof | |
| CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
| US20150125558A1 (en) | Pleuropterus multiflorus extract and dipsacus asperoides extract for secreting insulin-like growth factor and promoting bone structure growth, and method for preparing same | |
| CN106749729B (en) | A kind of Smilacina japonica polysaccharide and its preparation method and application | |
| CN101690813B (en) | Concentrated freeze-dried yolk antibody composite preparation for Newcastle disease and preparation process thereof | |
| CN107056959A (en) | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation | |
| CN105687036A (en) | Rhizoma bletillae skin care product and method for preparing same | |
| CN103584091B (en) | A kind of guarantor with raising immunity, hypolipemic function builds food and preparation method thereof | |
| CN102764294B (en) | Cough relieving and sputum eliminating combination and preparation method thereof | |
| CN104288344A (en) | Applications of a Pu'er tea extract product in preparation of medicines or foods adjusting intestinal flora and relaxing the bowels | |
| WO2016141774A1 (en) | Uses of jilin ginseng oligopeptide in preparing food product or healthcare food product for improving and enhancing sexual function | |
| CN102283859A (en) | Application of dicliptera chinensis polysaccharide | |
| CN104403020A (en) | Semi-bionic lentinan extraction method | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN102816226A (en) | Preparation method of porcine small intestine antibacterial peptides PR39 | |
| TWI763916B (en) | Cyanobacterial extracts, processes for preparing the same and uses thereof | |
| CN102861333B (en) | High-activity composite antibody oral preparation for resisting bursa fabricius viruses and influenza viruses of chicken | |
| CN102772790B (en) | Compound echinacea purpurea preparation and preparation method and application thereof | |
| TWI618540B (en) | Composition for preventing renal toxicity caused by drug toxicity, preparation method thereof and Its use | |
| CN109294984A (en) | A kind of Lentinan and preparation method thereof of internal efficient amplification NK cell | |
| CN104758340B (en) | Coffee mesitoyl quinine acid extract and its preparation method and application in a kind of folium lonicerae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170818 |
|
| WD01 | Invention patent application deemed withdrawn after publication |